Separately, intranasal BG administration (3–30 mg/kg) effectively ameliorated PM2.5-induced combined allergic rhinitis and asthma syndrome through the suppression of STAT3 and MAPK activation [60]. Here, STAT3 is linked to allergic rhinitis.